CVS

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 29, 2007, for CVS Caremark Corporation (formerly CVS Corporation). The reporting period is significantly impacted by the completion of the Caremark Merger on March 22, 2007, which combined CVS's retail pharmacy operations with Caremark's pharmacy benefit management (PBM) services. The company operates two primary segments: Retail Pharmacy and Pharmacy Services.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased by $9.3 billion (13 weeks) and $22.6 billion (39 weeks) compared to the prior year. This growth is primarily attributable to the inclusion of Caremark's operations following the March 2007 merger and the 2006 acquisition of the Standalone Drug Business from Albertsons.
• Profitability: Net earnings surged 142.6% for the quarter and 91.4% for the year-to-date period. Operating profit more than doubled in both periods due to the merger and purchasing synergies.
• Balance Sheet Expansion: Total assets more than doubled to $54.9 billion, driven by the acquisition of Caremark. Goodwill increased from $3.2 billion to $23.4 billion, and intangible assets rose from $1.3 billion to $11.3 billion.
• Debt Levels: Total debt increased significantly to fund the merger and share repurchases. Long-term debt rose from $2.9 billion to $8.4 billion, while short-term debt decreased from $1.8 billion to $0.4 billion.

Guidance, Outlook, and Risks

• Outlook: Management expects to achieve significant benefits from purchasing scale and operating synergies. The company anticipates that cash flows from operations, supplemented by borrowings, will fund future growth and integration costs.
• Capital Allocation: The company executed a $2.5 billion Accelerated Share Repurchase (ASR) and a tender offer for 10.3 million shares. A $5.0 billion share repurchase program was authorized in May 2007.
• Key Risks:
  • Integration Risk: Uncertainty regarding the successful integration of Caremark and the realization of expected synergies.
  • Regulatory & Legal: Ongoing investigations by the SEC and DOJ regarding Caremark's stock option practices (closed without enforcement action as of August 2007), antitrust litigation regarding PBM practices, and qui tam lawsuits alleging False Claims Act violations.
  • Reimbursement Pressure: Continued efforts by third-party payors and government programs (Medicaid/Medicare Part D) to reduce prescription drug costs and reimbursement rates.
  • Generic Conversion: The shift from brand-name to generic drugs lowers revenue per prescription, though it increases gross profit rates.
• Unusual Items: The financial results include significant one-time costs related to the Caremark Merger, including $128.0 million in merger-related costs and accelerated stock option vesting expenses.

Investor Verification Checklist

• Verify the final valuation of Caremark's intangible assets and goodwill, as current figures are preliminary and subject to change.
• Monitor the status of the In Re Pharmacy Benefit Managers Antitrust Litigation and the qui tam lawsuit involving Medicaid claims.
• Assess the impact of the Deficit Reduction Act of 2005 on Medicaid reimbursement rates, scheduled to take effect in Q1 2008.
• Review the company's ability to realize projected operating synergies and cost savings from the merger.
• Track the company's debt service requirements given the increased leverage from the merger financing and share repurchases.